Supplement
The percentile data is represented in graphic form in Supplement Figure 4 . The percentile data is represented in graphic form in Supplement Figure 5 . The number of patients for age range 2-18y in this Table is 172 instead of 168 (Table I) because some of the patients were counted more than once when the patients were stratified by age for this table. These patients provided height measurements across >1 age range in this table.

Supplement Figure 1: Reference growth curves for MPS VI boys and girls.
Height for age measurements for boys (blue) and girls (red) are plotted per baseline uGAG levels (dotted lines for those with low baseline uGAG levels and dotted-dashed lines for high baseline uGAG levels.) Growth curve for the combined population is indicated by solid lines: blue line for boys and red for girls.
Supplement
Figure 2: Z-scores for age for MPS VI patients age 2-18 y and rapidly progressive disease.
The reference growth curves for rapidly progressing MPS VI patients (Figure 2 ) was used to plot z-scores of patients with pre-ERT uGAG levels of >200 µg/mg creatinine. All available pre-ERT (or those obtained within 1 month of ERT) height measurements were plotted with some patients contributing >1 data point as described in the methods. The number of baseline visits within +2 and -2 SD were 243 of 268 (90.7%) for the rapidly progressing patients.
Figure 3: Z-scores for age for MPS VI patients age 2-18 y and slowly progressive disease.
The reference growth curves for slowly progressing MPS VI patients (Figure 3 ) was used to plot z-scores of patients with pre-ERT uGAG levels of ≤200 µg/mg creatinine. All available pre-ERT (or those obtained within 1 month of ERT) height measurements were plotted with some patients contributing >1 data point as described in the methods. The number of baseline visits within +2 and -2 SD were 123 of 128 (96.1%) for the slowly progressing patients.
